Todd, Naomi, McNally, Ross, Alqudah, Abdelrahim, Jerotic, Djurdja, Suvakov, Sonja, Obradovic, Danilo, Hoch, Denise, Hombrebueno, Jose R, Campos, Guillermo Lopez, Watson, Chris J et al (show 14 more authors)
(2021)
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 106 (1).
pp. 26-41.
Abstract
<h4>Context</h4>Preeclampsia is a leading cardiovascular complication in pregnancy lacking effective diagnostic and treatment strategies.<h4>Objective</h4>To investigate the diagnostic and therapeutic target potential of the angiogenesis proteins, FK506-binding protein like (FKBPL) and CD44.<h4>Design and intervention</h4>FKBPL and CD44 plasma concentration or placental expression were determined in women pre- or postdiagnosis of preeclampsia. Trophoblast and endothelial cell function was assessed following mesenchymal stem cell (MSC) treatment and in the context of FKBPL signaling.<h4>Settings and participants</h4>Human samples prediagnosis (15 and 20 weeks of gestation; n ≥ 57), or postdiagnosis (n = 18 for plasma; n = 4 for placenta) of preeclampsia were used to determine FKBPL and CD44 levels, compared to healthy controls. Trophoblast or endothelial cells were exposed to low/high oxygen, and treated with MSC-conditioned media (MSC-CM) or a FKBPL overexpression plasmid.<h4>Main outcome measures</h4>Preeclampsia risk stratification and diagnostic potential of FKBPL and CD44 were investigated. MSC treatment effects and FKBPL-CD44 signaling in trophoblast and endothelial cells were assessed.<h4>Results</h4>The CD44/FKBPL ratio was reduced in placenta and plasma following clinical diagnosis of preeclampsia. At 20 weeks of gestation, a high plasma CD44/FKBPL ratio was independently associated with the 2.3-fold increased risk of preeclampsia (odds ratio = 2.3, 95% confidence interval [CI] 1.03-5.23, P = 0.04). In combination with high mean arterial blood pressure (>82.5 mmHg), the risk further increased to 3.9-fold (95% CI 1.30-11.84, P = 0.016). Both hypoxia and MSC-based therapy inhibited FKBPL-CD44 signaling, enhancing cell angiogenesis.<h4>Conclusions</h4>The FKBPL-CD44 pathway appears to have a central role in the pathogenesis of preeclampsia, showing promising utilities for early diagnostic and therapeutic purposes.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | preeclampsia, angiogenesis, risk prediction, mesenchymal stem cell treatment, trophoblast cells, endothelial function |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 20 Aug 2020 10:51 |
| Last Modified: | 11 Feb 2023 10:15 |
| DOI: | 10.1210/clinem/dgaa403 |
| Open Access URL: | https://academic.oup.com/jcem/advance-article/doi/... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3098212 |
Dimensions
Dimensions
